Recent results of a phase II trial showed favourable responses to dasatinib in patients with imatinib-resistant/intolerant or newly diagnosed chronic myeloid leukaemia in chronic phase (CML-CP), according to findings presented at the 22nd Congress of European Hematology Association (EHA 2017) held in Madrid, Spain.
Two trials on chimeric antigen receptor (CAR) T cell therapy showed positive responses in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL) or transformed follicular lymphoma (TFL), according to findings presented at the recent European Hematology Congress 2017 held in Madrid, Spain.
Denosumab is noniferior to zoledronic acid in delaying skeletal-related events (SREs) with less renal toxicity in patients with multiple myeloma, according to a study presented at the EHA Congress 2017 in Madrid, Spain.
Elderly cancer patients on anticoagulant therapy are at least nine times more likely to die within 7 days after a major bleeding event than after a venous thromboembolism (VTE) recurrence, suggests a study presented at the EHA Congress 2017 in Madrid, Spain.
Blinatumomab more than doubled the overall survival (OS) vs standard-of-care (SOC) chemotherapy in the first salvage regimen in patients with Philadelphia chromosome-negative relapsed/refractory precursor B-cell acute lymphoblastic leukaemia (R/R BCP-ALL), according to a subset analysis of the TOWER* trial presented at the European Hematology Association (EHA) Congress 2017 held in Madrid, Spain.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.
The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.